ePrivacy and GPDR Cookie Consent by TermsFeed Generator
Join Us for a Live Webinar on June 28, 2022. From Genetic Risk Variant Discovery to Functional Validation in Autoimmune DiseasesRegister Now

About the Webinar

Exciting new developments in 3D genomic technologies have increasingly enabled researchers to uncover novel disease mechanisms and identify new therapeutic targets in cancer. In this webinar, hear about the results of a collaboration between scientists at Arima Genomics and NYU to identify the genetic drivers of previously undiagnosable tumors.

Key Takeaways

  • Recent patient case studies show how Hi-C technology identifies both existing and novel gene fusions and complex rearrangements.
  • 3D genome analysis adds diagnostic value by identifying novel molecular drivers and potential therapeutic targets in tumors with no previously detectable drivers.
  • Hi-C technology resolves clinical and molecular controversies and enables analysis of archival FFPE samples with failed or inconclusive molecular results.

Meet the Speakers

Matija Snuderl, MD

Director of Molecular Pathology and Diagnostics at NYU Grossman School of Medicine

Dr. Matija Snuderl is a neuropathologist at NYU Langone whose clinical research focuses on identifying novel biomarkers for diagnosis and therapy. Dr. Snuderl's laboratory studies cancer genetics and epigenetics and examines the molecular differences between tumors at the cellular level.

Anthony Schmitt, PhD

SVP of Science at Arima Genomics

Anthony Schmitt has led the development of the core Arima Hi-C chemistry and technology platform since Arima’s inception, contributed to core inventions and technology development grants, and continues to lead the R&D programs for targeted chromosome conformation capture techniques.